VYCO — what changed in the latest 10-Q
A section-by-section comparison of VYCO's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-05-15 vs the prior 10-Q · 2025-11-14
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +17 | −29 | ~3 | 10 |
| Controls & procedures | Text added/removed | 0 | 0 | ~1 | 5 |
| Legal proceedings | Text added/removed | 0 | 0 | ~1 | 0 |
| Other information | Text added/removed | 0 | 0 | ~1 | 9 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3), Risk factors
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-05-15
Comparison of the Three Months Ended March 31, 2026 to the Three Months Ended March 31, 2025
Vycor Medical recorded revenue of $440,441 from the sale of its products for the three months ended March 31, 2026, an increase of $21,921, or 5%, over the same period in 2025, most of the increase being from growth in international markets. Gross margin of 82% was recorded for the three months ende…
NovaVision recorded revenues of $18,099 for the three months ended March 31, 2026, an increase of $241, or 1%, over the same period in 2025. Gross margin was 89% for the three months ended March 31, 2026, compared to 94% for the same period in 2025 due to higher chinrest costs.
Research & Development expenses were $0 for the three months ended March 31, 2026 compared to $5,762 for the same period in 2025.
Selling, general and administrative expenses decreased by $35,333 to $315,365 for the three months ended March 31, 2026 from $350,698 for the same period in 2025. Included within Selling, General and Administrative Expenses are non-cash charges for stock-based compensation as the result of amortizin…
Text removed vs the prior filing · source: 10-Q · 2025-11-14
In August 2024 the Company engaged the services of Maxim Group LLC to assist in its strategy to accelerate the growth of the Company through strategic acquisitions and partnerships.
Comparison of the Three Months Ended September 30, 2025 to the Three Months Ended September 30, 2024
Vycor Medical recorded revenue of $492,102 from the sale of its products for the three months ended September 30, 2025, an increase of $119,265, or 32%, over the same period in 2024, most of the increase being from growth in the US. Gross margin of 88% and 90% was recorded for the three months ended…
NovaVision recorded revenues of $21,690 for the three months ended September 30, 2025, an increase of $3,675, or 20%, over the same period in 2024. Gross margin was 95% for the three months ended September 30, 2025, compared to 92% for the same period in 2024.
Research & Development expenses were $0 for the three months ended September 30, 2025 compared to $6,425 for the same period in 2024.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice